Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Terns Pharmaceuticals Inc (TERN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TERN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -33.92% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 223.48M USD | Price to earnings Ratio - | 1Y Target Price 19.06 |
Price to earnings Ratio - | 1Y Target Price 19.06 | ||
Volume (30-day avg) 1038449 | Beta -0.31 | 52 Weeks Range 2.56 - 11.40 | Updated Date 04/2/2025 |
52 Weeks Range 2.56 - 11.40 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate -0.3002 | Actual -0.24 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.13% | Return on Equity (TTM) -29.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -133335070 | Price to Sales(TTM) 302.64 |
Enterprise Value -133335070 | Price to Sales(TTM) 302.64 | ||
Enterprise Value to Revenue 337.47 | Enterprise Value to EBITDA -5.8 | Shares Outstanding 87297600 | Shares Floating 53711612 |
Shares Outstanding 87297600 | Shares Floating 53711612 | ||
Percent Insiders 0.24 | Percent Institutions 105.27 |
Analyst Ratings
Rating 4.33 | Target Price 19.06 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Terns Pharmaceuticals Inc
Company Overview
History and Background
Terns Pharmaceuticals, Inc. is a global biopharmaceutical company founded in 2016. It focuses on developing therapies for chronic liver diseases, including non-alcoholic steatohepatitis (NASH) and other diseases. The company has evolved from early-stage research to clinical development, conducting trials for its drug candidates.
Core Business Areas
- NASH Program: Develops small-molecule therapeutics for NASH, including combination therapies targeting different pathways. Key focus is on FXR agonists and other NASH targets.
- Oncology Program: Developing small-molecule therapeutics for oncology. Primary program is focused on an allosteric inhibitor of the tyrosine kinase receptor SHP2
Leadership and Structure
The leadership team includes Senthil Sundaram (CEO), Jack Zhang (CFO). The company has a typical biotech structure with research, development, clinical, and commercial functions. It also has a Board of Directors to oversee operations.
Top Products and Market Share
Key Offerings
- TERN-501: A thyroid hormone receptor beta (THR-u03b2) agonist for NASH treatment. Currently in clinical development. Competitors include Viking Therapeutics (VKTX) with VK2809.
- TERN-701: An allosteric inhibitor of SHP2 for oncology treatment. Currently in clinical development. Competitors include Relay Therapeutics (RLAY) with RLY-4008.
- TERN-601: An oral glucagon-like peptide-1 receptor (GLP-1R) agonist for NASH. Currently in clinical development. Competitors include Eli Lilly (LLY) and Novo Nordisk (NVO).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. NASH represents a significant unmet medical need, driving substantial investment and innovation. Oncology is also a very competitive field
Positioning
Terns is a clinical-stage biotech company focused on NASH and oncology. Its competitive advantage lies in its diversified pipeline and innovative combination therapy approach.
Total Addressable Market (TAM)
The NASH market is estimated to reach $20-35 billion by the late 2020s. Terns is positioned to capture a portion of this market with its diverse pipeline. The global oncology market is significantly larger
Upturn SWOT Analysis
Strengths
- Diverse pipeline of NASH assets
- Experienced management team
- Combination therapy approach
- Strong intellectual property position
- Advancing pipeline of oncology assets
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on clinical trial success
- Competition from larger pharmaceutical companies
- Limited revenue streams
Opportunities
- Positive clinical trial results for NASH assets
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or licensing
- Approval and commercialization of NASH therapies
- Further oncology clinical advancement
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other NASH therapies
- Patent challenges
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- Viking Therapeutics (VKTX)
- Madrigal Pharmaceuticals (MDGL)
- Akero Therapeutics (AKRO)
- Relay Therapeutics (RLAY)
Competitive Landscape
Terns faces competition from larger, more established pharmaceutical companies. Its advantages include a diversified pipeline and innovative combination therapy approach. Disadvantages include limited financial resources and the risks associated with clinical-stage development.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline expansion and clinical trial progress.
Future Projections: Future growth depends on clinical trial success and potential commercialization of NASH and Oncology therapies. Analyst estimates vary but generally project revenue growth upon product approval.
Recent Initiatives: Recent initiatives include advancing TERN-501, TERN-701, and TERN-601 through clinical trials, expanding the NASH pipeline through licensing, and engaging in collaborations with other pharmaceutical companies.
Summary
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on NASH and oncology. They have a diverse pipeline with multiple ongoing clinical trials. The company's success depends on positive clinical trial results and successful commercialization of their therapies. Competition is a threat, especially from large, established firms. Terns' innovation and combination therapy approach could set them apart.
Similar Companies
- VKTX
- AKRO
- MDGL
- RLAY
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- ClinicalTrials.gov
- Yahoo Finance
- Google Finance
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimated based on current pipeline status and potential future sales. Actual results may vary. Financial data is from publicly available sources and may be subject to change. This analysis uses AI and may have errors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Terns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO & Director Ms. Amy L. Burroughs M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.ternspharma.com |
Full time employees 59 | Website https://www.ternspharma.com | ||
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.